AstraZeneca PLC’s impressive rebound continued in the third quarter. The UK firm beat market sales and profit forecasts, led by its oncology portfolio and marked by a heady expansion in emerging markets, with sales in China up 40% at constant exchange rates.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?